[Recent advances in the treatment of chronic myeloid leukemia].

Authors

Seiichiro Katagiri

Published in

[Rinsho ketsueki] The Japanese journal of clinical hematology. Volume 67. Issue 7. Pages 711-715.

Abstract

The introduction of tyrosine kinase inhibitors (TKIs) has substantially improved outcomes for chronic-phase chronic myeloid leukemia (CML-CP). Furthermore, the development of ABL myristoyl pocket inhibitors that target specific molecular pathways has enabled adoption of treatment strategies with fewer adverse events. However, the clinical significance of somatic mutations in genes other than ABL1 in treatment resistance is attracting increasing attention. Additionally, novel TKIs and STAMP inhibitors are under development, and are expected to further improve CML management. This article summarizes the frequency and clinical impact of somatic mutations in CML-CP and reviews promising novel TKIs and STAMP inhibitors.

PMID:
42543639
Bibliographic data and abstract were imported from PubMed on 03 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.